Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 ( PD ‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer ( NSCLC ). Because the baseline advanced lung cancer inflammation index ( ALI ) is reportedly associated with patient outcomes, we investigated whether the pretreatment ALI is prognostic in NSCLC patients treated with nivolumab. We retrospectively reviewed the medical records of all patients treated with...